The tweet was deleted by the author.
But we saved everything 🙂.
Marianne De Backer, CEO of Vir Biotechnology, joined fellow members of the IAmBiotech Board of Directors to kick off BIO2026.
The event brings together leading figures from the biotech ecosystem to explore new ways to advance innovation in the U.S., with a focus on enhancing the delivery of meaningful treatments for patients. De Backer's participation reflects a strategic effort to foster industry collaboration and shape the future of biotechnology.
View post on X Loading...
Vir Biotechnology has recently shared early Phase 1 data for VIR-5500 in metastatic prostate cancer and expanded its collaboration with Astellas at ASCO2026. The company also presented data at EASL2026 on the impact of BMI on ALT normalization in chronic hepatitis delta patients from the Phase 2 SOLSTICE study. These developments reflect Vir's ongoing focus on advancing clinical research across multiple indications.